Search

Your search keyword '"Ennishi, Daisuke"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Ennishi, Daisuke" Remove constraint Author: "Ennishi, Daisuke" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
32 results on '"Ennishi, Daisuke"'

Search Results

1. Supplementary Table S11 and 15 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

2. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

3. Supplementary Table S8-9 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

4. Supplementary Table S12-14 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

5. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

6. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

7. Supplementary Table S2 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

8. Supplementary Table S3 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

9. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

10. Supplementary Table S6 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

11. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

12. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

13. Supplementary Table S1 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

14. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

15. Supplementary Table S3 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

16. Supplementary Table S4 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

17. Supplementary Table S1 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

18. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

19. Supplementary Table S4 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

20. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

21. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

22. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

23. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

24. Supplementary Table S2 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

25. Supplementary Table S6 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

26. Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

27. Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

29. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

30. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

31. Abstract IA18: Functional characterization of the tumor suppressor lysine-specific methyltransferase KMT2D in lymphoma

32. An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

Catalog

Books, media, physical & digital resources